5 Free Dividend Stocks for 2022
Could these top payout stocks be part of the greatest wealth-creating tool in history?
Learn More.
Marcus Boehm Insider Alerts

Get notified the next time Marcus Boehm buys or sells Vyant Bio stock. Enter your email address below to get our daily insider buying and selling report.

Marcus Boehm Insider Information

Director of Vyant Bio


Mr. Marcus Boehm is the Director of Vyant Bio.

What is Marcus Boehm's net worth?

The estimated net worth of Marcus Boehm is at least $126,629.12 as of May 28th, 2021. Mr. Boehm owns 98,929 shares of Vyant Bio stock worth more than $126,629 as of January 20th. This net worth evaluation does not reflect any other assets that Mr. Boehm may own. Learn More.

How do I contact Marcus Boehm?

The corporate mailing address for Mr. Boehm and other Vyant Bio executives is 2370 State Route 70 Suite 310, Cherry Hill NJ, 08002. Vyant Bio can also be reached via phone at (201) 479-1357 and via email at [email protected]

Has Marcus Boehm been buying or selling shares of Vyant Bio?

Marcus Boehm has not been actively trading shares of Vyant Bio during the past quarter. Most recently, on Monday, December 6th, Marcus Boehm bought 5,000 shares of Vyant Bio stock. The stock was acquired at an average cost of $1.69 per share, with a total value of $8,450.00.

Who are Vyant Bio's active insiders?

Vyant Bio's insider roster includes Marcus Boehm (Director), R. Fletcher (Director), Paul Hansen (Director), John Roberts (CEO), and Yung-Ping Yeh (Insider).

Are insiders buying or selling shares of Vyant Bio?

During the last twelve months, Vyant Bio insiders bought shares 16 times. They purchased a total of 115,687 shares worth more than $327,974.21. The most recent insider tranaction occured on December, 6th when Director Marcus Boehm bought 5,000 shares worth more than $8,450.00. Insiders at Vyant Bio own 15.0 % of the company.

Information on this page was last updated on 12/6/2021.

Marcus Boehm Insider Trading History at Vyant Bio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/6/2021Buy5,000$1.69$8,450.00View SEC Filing Icon  
10/27/2021Buy5,000$2.10$10,500.00View SEC Filing Icon  
9/29/2021Buy5,000$2.44$12,200.00View SEC Filing Icon  
8/25/2021Buy5,000$2.58$12,900.00View SEC Filing Icon  
7/28/2021Buy5,000$2.92$14,600.00View SEC Filing Icon  
5/28/2021Buy5,000$3.68$18,400.0098,929View SEC Filing Icon  
See Full Table

Marcus Boehm Buying and Selling Activity at Vyant Bio

This chart shows Marcus Boehm's buying and selling at Vyant Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vyant Bio Company Overview

Vyant Bio logo
Vyant Bio, Inc. is emerging as an advanced biotechnology drug discovery company. The firm is focused on human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners, as well as for its proprietary pipeline. The company with capabilities in data, science (both biology and chemistry), engineering, and regulatory, it rapidly identifying small and large molecule therapeutics and derisking decision making through multiple in silico, in vitro, and in vivo modalities. It leveraging these modalities, the company is able to capitalize on repurposed and novel compounds and then partner with others to further develop and commercialize valuable therapeutics and new treatments for patients. It operates two wholly-owned subsidiaries, StemoniX and vivoPharm. Vyant Bio was founded in 1999 and is headquartered in Cherry Hill, NJ.
Read More

Today's Range

Now: $1.28
Low: $1.23
High: $1.30

50 Day Range

MA: $1.64
Low: $1.21
High: $2.25

2 Week Range

Now: $1.28
Low: $1.20
High: $17.50

Volume

25,340 shs

Average Volume

67,578 shs

Market Capitalization

$37.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.17
5 Tech Stocks to Buy Immediately
Eric Fry, one of America's top Investment Strategists, provides his latest report 5 Top Stocks for 2022.

You can't afford to miss out on the once in a decade chance to buy after the recent dip in the markets.
Download this hot-off-the-presses research report now. It’s yours FREE.